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Abstract: Herpetic keratitis is caused by herpes simplex virus (HSV) and is a common cause 
of corneal blindness. Following a primary ocular herpetic infection, latency of the virus occurs, 
followed by subsequent recurrences of herpetic keratitis. Such recurrences may lead to structural 
damage of the cornea. Recurrent herpetic keratitis is a common indication for corneal transplan-
tation. Recurrences of herpetic keratitis in the corneal graft may lead to corneal graft rejection. 
Several antiviral agents for HSV are available, including the thymidine analogs. Prolonged use 
of thymidine analogs may lead to toxicity of the ocular surface, including epithelial keratitis, 
corneal ulcers, follicular conjunctivitis, and punctal occlusions. Availability of topical antiviral 
agents that are safe and effective in the treatment and prophylaxis of herpetic keratitis is highly 
desirable. Ganciclovir is a potent inhibitor of members of the herpes virus family. The drug has 
been used systemically for the treatment of cytomegalovirus (CMV) retinitis. Its hematologic 
toxicity secondary to systemic administration led to its limited use in herpetic infections. On 
the other hand, topical ganciclovir has been shown to be as safe and effective as acyclovir in the 
treatment of herpetic epithelial keratitis. Furthermore, topical ganciclovir can reach therapeutic 
levels in the cornea and aqueous humor following topical application. Several clinical trials 
have shown that topical ganciclovir 0.15% ophthalmic gel is safe and effective in the treatment 
and prophylaxis of herpetic epithelial disease. Long-term use of ganciclovir ophthalmic gel in 
patients with penetrating keratoplasty following herpetic keratitis has prevented recurrences of 
the disease. Topical ganciclovir ophthalmic gel is well tolerated, does not cause toxic effects 
on the ocular surface, and does not cause hematologic abnormalities. Clinical studies have 
underscored the potential role of ganciclovir ophthalmic gel in the treatment and prophylaxis 
of herpetic epithelial keratitis. Future randomized, controlled, multicenter, prospective clinical 
trials are needed to assess the long-term safety and efficacy of topical ganciclovir in the treat-
ment and prevention of herpetic keratitis and uveitis.
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Introduction
The ocular and adnexal structures are frequently the target of infection by herpes 
simplex virus (HSV). HSV is involved in the pathogenesis of several ocular disorders 
and may lead to blepharitis, vesicular dermatitis of the eyelids, conjunctivitis, kera-
titis, trabeculitis, anterior uveitis, acute retinal necrosis syndrome, retinitis, and optic 
neuritis (Table 1). Herpetic corneal epithelial infections are by far the most common 
ocular manifestation. Herpetic ocular disease may be primary, latent, or recurrent 
(secondary).1–3 Ocular infection in a patient who is not immune to the virus and not 
previously infected is referred to as primary disease. Patient may develop viral latency Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table  1  Ocular  manifestations  of  herpes  simplex  of  the  eye   
and adnexa
Eyelid
  Dermatitis and vesicular eruption and ulceration
  Punctal occlusion
Conjunctiva
  Follicular conjunctivitis
  Membranous conjunctivitis
  Conjunctival cicatrization
Episclera/sclera
  Episcleritis
  Scleritis
Cornea
  A. Epithelium
      Dendritic or geographic ulcer
  B. Stromal
      Necrotizing keratitis
      Non-necrotizing keratitis
      Disciform keratitis
      Interstitial keratitis
  C. Endothelium
      Endotheliitis
  D. Corneal complications
      Corneal vascularization, corneal scarring
      Trophic keratitis
      Lipid keratopathy
      Corneal perforation
      Postinflammatory corneal ectasia
Uvea
      Acute anterior granulomatous or nongranulomatous uveitis
      Trabeculitis
      Secondary glaucoma
      Iris atrophy
      Iridocyclitis and trabeculitis
Retina and optic nerve
      Vitritis
      Acute retinal necrosis
      Retinal vasculitis
      Optic neuritis
after a primary infection and the virus stays dormant in the 
nerve ganglia. It may later cause recurrent clinical manifes-
tations. Ocular infections in adults are predominantly due 
to HSV Type 1. Genito-ocular spread can occur and may 
be caused by HSV Type 2, but is less common. The disease 
may also be related to postnatal infection with HSV Type 1. 
An intrauterine- or neonatal birth canal-acquired infection 
with HSV Type 2 may occur. In herpes-infected neonates 
and infants without central nervous system involvement, 
keratitis occurs in 80% of cases and conjunctivitis occurs in 
approximately 10% of cases. Visual loss in ocular herpetic 
infection may be due to keratitis, uveitis, cataract, or glau-
coma, while in neonatal herpetic infections the visual loss is 
commonly due to optic atrophy and chorioretinitis. Following 
a primary infection, the disease may recur in the cornea and 
may result in epithelial keratitis. Recurrent epithelial keratitis 
may stay in the epithelial layer or may involve the deeper 
stromal layer and endothelium.
Risk factors for HSV reactivation are well known and 
include stress, exposure to ultraviolet radiation, menstruation, 
fever, use and abuse of corticosteroids, and trauma including 
surgical trauma.4,5 The disease is usually unilateral. Bilat-
eral herpetic keratitis may occur in patients with systemic 
diseases, such as atopic disorders, malignancy, debilitating 
illnesses, or in patients on immunosuppressive agents.2
Herpetic keratitis is a common cause of ocular morbidity 
and represents the most common cause of corneal blindness.1 
Recurrent herpetic keratitis is also a common indication for cor-
neal transplantation. Recurrences of herpetic epith  elial keratitis 
may occur in the corneal graft and result in   structural damage 
of the cornea, leading to corneal graft rejection and failure. 
The ocular disease could take one of two forms. The first is the 
primary ocular disease occurring in a patient who has no previ-
ous exposure to herpes virus, and the second is latent disease in 
patients who have dormant HSV in the nerve ganglia. Primary 
herpetic disease can be clinical or   subclinical. Viral reactivation 
in latency may lead to   involvement of the lids, conjunctiva, 
cornea, uvea, retina, and/or optic nerve. Recurrent disease of 
the cornea is the most common, occurs in the latent phase, and 
may be epithelial, stromal, endothelial, or disciform.
There are several antiviral agents that are effective against 
HSV , and these include idoxuridine, vidarabine, trifluridine, 
acyclovir, famciclovir, valganciclovir, valacyclovir, and 
cidofovir. Idoxuridine and trifluridine act as thymidine ana-
logs by formation of defective viral DNA molecules due to 
inhibition of DNA polymerase.3 Vidarabine, a purine analog, 
inhibits viral DNA polymerase and is incorporated by the 
viral DNA molecule. Idoxuridine, trifluridine, and vidara-
bine cause corneal epithelial toxicity because of their non-
selective action on infected and noninfected host cell DNA 
molecules. Prolonged use of thymidine analogs, however, 
may cause ocular surface toxicity. Acyclovir is activated by 
HSV thymidine kinase to the monophosphate form and by 
cellular enzymes to acyclovir triphosphate, causing inhibi-
tion of Herpes virus DNA polymerase. Topical acyclovir is 
available as a 3% ophthalmic ointment for the treatment of 
HSV corneal epithelial.
Several studies have shown that ganciclovir is highly effec-
tive in the inhibition of HSV Type 1 and Type 2. Systemic 
ganciclovir is indicated for sight-threatening CMV retinitis 
in severely immunocompromised people, CMV pneumonitis 
in bone marrow transplant recipients, prevention of CMV 
disease in bone marrow and solid organ transplant   recipients, Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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and confirmed CMV retinitis in people with acquired 
  immunodeficiency syndrome (intravitreal implant).
The purpose of this paper is to provide a critical review 
of topical ganciclovir in the treatment of acute herpetic 
epithelial keratitis.
Pharmacology and pharmacokinetics
Ganciclovir (Figure 1) is an antiviral agent that is similar to 
acyclovir (Figure 2). Acyclovir is used for herpetic keratitis, 
whereas ganciclovir is used to treat or prevent cytomegalo-
virus (CMV) infections. Ganciclovir sodium is marketed 
under the trade names Cytovene® and Cymevene® (Roche). 
Ganciclovir for intraocular inserts is marketed under the trade 
name Vitrasert® (Bausch and Lomb). The device is approved 
for the treatment of CMV retinitis. A prodrug form with 
improved oral bioavailability (valganciclovir) is also avail-
able. Topical ganciclovir is available from Laboratoires Théa 
(Louis-Bleriot, Clermont-Ferrand, France) and is marketed 
under the names Virgan® and Zirgan® as 1.5 mg/g eye gel 
in tubes of 5 g each. The other ingredients in ganciclovir are 
carbomer (Carbopol® 974P), sorbitol, sodium chloride, and 
benzalkonium chloride.
Ganciclovir is a nucleoside analog that is selectively 
phosphorylated by virus-encoded thymidine kinase, and 
is subsequently phosphorylated by cellular enzymes.1 
  Ganciclovir is converted into ganciclovir monophosphate and 
then to ganciclovir diphosphate and finally, to ganciclovir 
triphosphate. Ganciclovir triphosphate inhibits Herpes virus 
DNA polymerase and arrests HSV replication.6–9 Following 
topical application of ganciclovir, it has been shown that 
the drug can penetrate the corneal stroma and can reach the 
aqueous humor in therapeutic levels.9
In a study by Castela et al,9 ganciclovir ophthalmic gel 
was prepared in Carbomer 934P (NF XVII, Transphyto SA, 
Clermont-Ferrand, France). The drug-free vehicle was used 
as a placebo and the ganciclovir concentration levels of the 
tested gels were 0.0125%, 0.05%, and 0.2%. The investiga-
tors studied the effects of ganciclovir ophthalmic gel on HSV 
keratitis in rabbits. The efficacy of the three ganciclovir gel 
strengths were compared with placebo and 3% acyclovir 
ophthalmic ointment using an HSV Type 1 rabbit keratitis 
animal model. All three ganciclovir concentrations showed 
clinical efficacy and significant reduction of corneal ulcer 
area, clouding, and vascularization (P , 0.05) and rapid 
inhibition of HSV shedding in tear films. The distribution of 
ganciclovir and acyclovir in the rabbit eyes were determined 
by high performance liquid chromatography. Both ganciclo-
vir and acyclovir were found to reach higher levels in the 
cornea than in the aqueous humor. No ocular toxicity was 
noted in this study. Corneal penetration of ganciclovir was 
due to the small size of the ganciclovir molecule, its high 
lipophilicity, and its high cellular affinity resulting from its 
structural analogy with the endogenous nucleosides. This 
may explain the high diffusion of ganciclovir in the corneal 
epithelium (pKa 2.2 and 9.4 at pH 6.5–7.4). The destruction 
of the corneal epithelium by the virus allows penetration 
of the drug into the cornea so that it can reach the anterior 
  chamber. Ganciclovir was found in the aqueous humor of 
healthy rabbits three hours after a series of six administrations 
of the gel formulation.9 The level of concentration was depen-
dent on the ganciclovir dosage and frequency of application. 
Ganciclovir has poor water solubility, and its affinity for 
melanin in cells explains its preferential distribution in solid 
ocular tissues, such as the iris, compared with the aqueous 
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humor. Ganciclovir was recovered from the aqueous humor 
four hours after the last topical administration of ganciclovir 
0.2%, and this could be due to the slow diffusion of the drug 
from the cornea to the aqueous humor.9
The physiochemical properties of acyclovir and 
  ganciclovir are similar, and this explains the similarity in 
the ocular tissue distribution. The tissue concentrations are 
of the same order of magnitude when comparing ganci-
clovir ophthalmic gel 0.15% with 3% acyclovir ointment 
despite the difference in dosage strength. Furthermore, the 
plasma concentration four hours after the administration 
of ganciclovir gel was very low. This illustrates the lim-
ited plasma diffusion of the drug and its lack of systemic 
toxicity. With regard to the experimental design, one has 
to keep in mind that the rabbit model of herpetic keratitis 
is different from that of human ocular herpes. Extrapo-
lation of the findings from the animal model to humans 
should be done with caution. The intraocular diffusion of 
ganciclovir may permit its use in the treatment of herpetic 
keratouveitis. The low plasma ganciclovir concentration 
after chronic gel application limits the risk of systemic 
toxicity. The efficacy of ganciclovir was observed in vitro 
and in vivo against HSV strains resistant to both idoxuri-
dine and acyclovir.10
Therapeutic interventions for HSV 
epithelial keratitis
Wilhelmus11 performed a systematic review of the litera-
ture reported in the Cochrane Database. Surveys of ocular 
antiviral drugs for HSV eye disease were evaluated in a 
systematic review of all comparative clinical studies. The 
review revealed that antiviral agents are effective and 
nearly equivalent in their efficacy. The combination of a 
nucleoside antiviral agent with either debridement of the 
epithelium or with interferon seems to speed up healing 
of the epithelium. The studies that were reviewed did not 
consider the size of the lesion patients had prior to treat-
ment. Debridement in combination with antiviral therapy 
appears to be more effective than antiviral chemotherapy 
alone, but this issue remains inconclusive. Removal of 
infected epithelial cells by debridement appears to be 
effective, but antiviral agents against HSV are needed 
to prevent recrudescence of epithelial keratitis.1 Anti-
viral agents did not increase the speed of healing when 
compared with debridement, but reduced the risks of 
recurrence of epithelial keratitis. Ganciclovir appear to 
be as effective as other antiviral agents in the treatment 
of herpetic keratitis.1
Ganciclovir ophthalmic gel  
in herpetic keratitis
Topical ganciclovir has been studied in animal models of 
herpetic keratitis and healthy volunteers, and in several pro-
spective, randomized clinical trials.12–17 Topical ganciclovir 
has been found to be safe and effective in the treatment of 
herpetic epithelial keratitis. A randomized prospective clini-
cal trial was carried out in Africa and Europe. Sixty-seven 
patients were included in the first clinical trial in Africa, 
and 37 patients were included in the second clinical trial 
in Europe.12 The results of these two clinical trials showed 
no statistically significant difference between ganciclovir 
0.15% gel and acyclovir 3% ophthalmic ointment in patients 
with herpetic epithelial keratitis. Healing was achieved 
within one week in 85% of patients treated with ganciclovir 
0.15% gel compared with 32% of patients treated with acy-
clovir ointment. On the other hand, 83% of patients achieved 
healing within one week following ganciclovir 0.15% gel 
compared with 72% in patients treated with acyclovir 
ointment. There were fewer complaints (stinging, burning 
sensation, blurring of vision) in the ganciclovir group than 
in the acyclovir group. Patients treated with ophthalmic 
acyclovir ointment complained of irritation and blurring of 
vision. The findings of these two clinical trials support the 
fact that ganciclovir gel is safe and effective in the treat-
ment of HSV epithelial keratitis, and that in this regard it is 
superior to acyclovir.12
Hoh et al18 studied the effects of topical ganciclovir gel 
and acyclovir ointment in the treatment of HSV dendritic 
keratitis in a multicenter, prospective, randomized clinical 
trial. Their findings demonstrated that topical ganciclovir 
ophthalmic gel was as safe and effective as acyclovir in 
the treatment of herpetic epithelial keratitis. There was no 
significant difference in adverse effects between the two 
treatment modalities.
Following topical application, ganciclovir has been 
shown to penetrate the corneal stroma and to reach the aque-
ous humor in therapeutic levels.18 It has been shown to be as 
effective as acyclovir in the treatment of herpetic keratitis 
in humans.10,18 The effects of topical ganciclovir 0.15% gel 
were studied in 16 consecutive patients with corneal grafts 
and previous recurrences of herpetic keratitis.19 Topical 
ganciclovir was found to be safe and effective in this open, 
non-randomized study. Furthermore, long-term topical gan-
ciclovir afforded protection against recurrence of the disease 
in patients who had undergone penetrating keratoplasty.19
Patients undergoing corneal transplantation for herpetic 
corneal disease may be treated with topical   prophylactic Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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antiviral agents. Such patients have latent HSV in the 
trigeminal ganglion and may develop recurrence of 
the disease in the graft, with subsequent corneal graft 
failure.15,16,20,21 These patients may be given either acyclo-
vir 3% ophthalmic ointment or ganciclovir 0.15% gel four 
times daily in conjunction with topical prednisolone 1% eye 
drops. Ganciclovir 0.15% gel may help in the prevention 
of recurrences of herpetic keratitis in patients undergoing 
corneal transplantation. Epithelial disease improvement 
and healing of the ulcer can occur within one week of 
treatment with topical ganciclovir.10,18,19 Ganciclovir given 
in a gel form is easy to apply and does not cause blurring 
of vision, unlike acyclovir petrolatum-based ophthalmic 
ointment (Table 2). The drug is well tolerated and has no 
toxic effects on the ocular surface. Corneal tissue absorption 
of ganciclovir can reach therapeutic levels and be found in 
the aqueous humor following topical application.9,12 Figures 
3 and 4 show herpetic epithelial keratitis in two patients 
before and one week after treatment with ganciclovir 0.15% 
ophthalmic gel.
Ganciclovir is an important inducer of cell death. The 
efficacy of ganciclovir and acyclovir in inducing apoptosis 
in the HSV thymidine kinase system was compared by 
Shaw et al.13 Treatment with ganciclovir induced rapid 
apoptosis of HSV-infected cells. In contrast with up to seven 
days’ exposure, acyclovir did not induce apoptosis. Ganci-
clovir given topically did not cause systemic or hematologic 
adverse effects.
Long-term prophylaxis with ganciclovir in patients who 
had recurrent herpetic keratitis has not been studied. Future 
prospective, long-term clinical trials are needed to assess the 
safety and efficacy of topical ganciclovir prophylactic strate-
gies in the prevention of recurrent herpetic corneal disease.19 
Corneal transplantation for corneal scarring induced by HSV 
can restore vision and induce rapid recovery. Recurrence of 
herpetic keratitis in the transplanted graft, however, may 
lead to corneal graft rejection and decreased vision due to 
recurrence of HSV in the transplanted cornea.14–21 Therefore, 
it is recommended that long-term prophylaxis with topical 
ganciclovir gel or acyclovir ointment might help to prevent 
recurrence of the disease and subsequent graft rejection. It 
is generally agreed that corneal graft rejection and failure 
following corneal transplantation in patients with herpetic 
keratitis remains high and that the survival rate of the regraft 
is around 50%.21 The use of topical antiviral prophylaxis 
may help in the prevention of herpetic keratitis.15–17,19–23 
Long-term application of ganciclovir ophthalmic gel is an 
effective prophylaxis against herpetic keratitis in this group 
of patients and appears to be a good therapeutic strategy.21,24–26 
Recurrence of herpetic keratitis in the corneal graft follow-
ing penetrating keratoplasty poses a therapeutic dilemma. 
Herpetic keratitis may lead to corneal graft rejection which 
requires increased use of topical corticosteroids which may 
aggravate the herpetic infection.
Low-dose oral acyclovir has been shown to be effective 
in preventing recurrent genital herpes and appears to be a 
safe long-term prophylactic measure.27–29 Recurrences of 
genital herpes are prevented by long-term, low-dose oral 
acyclovir. This therapeutic strategy may also be applied to 
recurrences of ocular herpes. Prophylaxis in patients who 
have undergone penetrating keratoplasty for herpetic disease 
may prevent corneal graft failure. Oral acyclovir does not 
appear to be cost-effective for the prevention of HSV eye 
disease.22 Topical use of ganciclovir or acyclovir ointment 
as prophylaxis in patients with corneal grafts may spare 
the use of systemic oral antiviral agents such as acyclovir.21 
The good levels of ganciclovir in aqueous humor following 
topical application make this drug a potential therapeutic 
modality for the treatment and prophylaxis of herpetic 
keratouveitis. However, the long-term safety and efficacy of 
ganciclovir in the treatment of stromal keratitis and herpetic 
keratouveitis remain to be determined. Prospective clinical 
trials to assess the safety and efficacy of long-term topical 
ganciclovir ophthalmic gel in the prophylaxis of herpetic 
keratitis are needed.
Chee and Jap30 studied the effects of ganciclovir in 
patients with cytomegalovirus (CMV) uveitis. The CMV 
uveitis was diagnosed by the clinical findings and by aqueous 
polymerase chain reaction. The recurrence rate of anterior 
uveitis was significantly lower in patients who received 
topical ganciclovir gel than patients who were treated with 
systemic ganciclovir. Systemic and intravitreal ganciclovir 
and ganciclovir implant had good response rates but also had 
high recurrence rates. Ganciclovir 0.15% gel had moderate 
Table 2 Topical ganciclovir in herpetic keratitis
Good tolerance: no blurred vision, no stinging or burning sensation
Prolonged corneal contact time
Tonicity similar to tears
pH adjusted to a physiologic level
Sterilizable (autoclavable)
Long and stable shelf life
Potent broad spectrum antiviral agent
Selective effects on virus infected cells
Lubricant effects for corneal anesthesia
Penetration into the aqueous humor following topical application
As effective as acyclovir but at 20 × less concentration
No systemic adverse effectsClinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 3 A) Shows the right cornea of a 12-year-old boy with herpetic epithelial keratitis before treatment, and B) five days after treatment with topical ganciclovir 0.15% 
ophthalmic gel.
A
B
Figure 4 A) An 80-year-old male with geographic epithelial keratitis stained with fluorescein, and B) one week after treatment with ganciclovir 0.15% ophthalmic gel showing 
healing and re-epithelialization of the cornea.
response rates, but its recurrence rates were also lower than 
those of the other treatment modalities. Topical ganciclovir 
0.15% gel, therefore, may be considered for the treatment 
of CMV anterior uveitis.
Recent studies have focused on the ocular bioavailability 
of ganciclovir. In a study by Majumdar et al,31 a series of 
dipeptide monoester ganciclovir (GCV) prodrugs were evalu-
ated with the goal of improving the ocular bioavailability 
of ganciclovir topical ophthalmic solution. Val-Val-GCV, 
Tyr-Val-GCV , and Gly-Val-GCV were more stable in aque-
ous solution than Val-GCV. All three prodrugs had much 
higher aqueous solubility than the current drug. Transcorneal 
permeability of Val-GCV and Val-Val-GCV was seven-fold 
to eight-fold greater than that of GCV in the presence of a 
proton gradient and was significantly decreased in the pres-
ence of Gly-Pro. Val-Val-GCV 1% provided significantly Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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better therapeutic activity than trifluorothymidine against 
HSV-1 epithelial keratitis and was equivalent in its therapeu-
tic activity against stromal keratitis in the rabbit eye model 
of herpetic keratitis. Val-Val-GCV demonstrated excellent 
corneal permeability and chemical stability, high aqueous 
solubility, and substantial in vivo antiviral activity against 
HSV-1.
Topical ganciclovir 0.15% gel has been shown to be 
as effective as acyclovir in the treatment of active herpetic 
epithelial keratitis.32,33 Prospective, randomized clinical tri-
als are needed to assess the long-term safety and efficacy of 
topical ganciclovir in the prevention of recurrence of herpetic 
keratitis. Recurrent herpetic keratitis may lead to structural 
damage of the cornea and loss of vision. Herpes keratitis in 
a graft leads to rejection and graft failure. Prophylactic use 
of topical ganciclovir may prove to be safe in the prevention 
of recurrence of the disease. The intraocular penetration of 
topical ganciclovir in the aqueous humor may prove to be 
effective in the treatment of HSV keratouveitis, HSV , and 
CMV uveitis.
Prophylaxis may require a lower dose frequency, such 
as once or twice daily. The efficacy of such a therapeutic 
approach remains to be determined. In patients who had 
undergone penetrating keratoplasty for herpetic corneal 
scars, topical daily application of ganciclovir 0.15% gel 
may prove to be an effective prophylactic measure for the 
prevention of recurrences in the corneal graft. The dose 
and frequency remain to be determined. Most recurrences 
of HSV keratitis occur in the first year after the graft. Our 
patients with penetrating keratoplasty following herpetic 
keratitis are treated with ganciclovir 0.15% gel four times 
daily in the first week followed by two times daily for a period 
of one year. Future clinical trials are needed to assess the 
safety and efficacy of topical ganciclovir in the treatment 
and prevention of herpetic keratouveitis, and herpetic and 
CMV anterior uveitis.
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